Scope 2023: Emerging Biopharma Companies

The concept of sludge provides an invaluable lens for clinical research professionals in identifying and mitigating unnecessary friction and bottlenecks.

Following a webinar on what the clinical trials space will look like for the remainder of 2024, ACT caught up with Getz and Murphy to discuss their biggest takeaways.

A study conducted by the Tufts CSDD in collaboration with CluePoints and PwC revealed that slightly more than half of sponsors and contract research organizations have adopted risk-based quality management approaches.

Systematic review of over 800 retracted articles suggest that better identification of postretraction citations should be implemented.

In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.

Systematic review of 127 recent platform trials showed insufficient reporting of important trial information.